No alarm over Vytorin's SEAS trial, the FDA says
This article was originally published in Scrip
Executive Summary
The US FDAplans to review the SEAS trial relating toMerck/Schering-Plough’s Vytorin (ezetimibe plus simvastatin), but the agency's "early communication" about the ongoing safety review does not sound an alarm, and it says it awaits more data. The regulators note that two large, ongoing trials of Vytorin show no increased risk of cancer.